HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joseph P Costantino Selected Research

Doxorubicin (Adriamycin)

3/2017Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
1/201721-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
9/2015Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
11/2013Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
9/2013Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
1/2012Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
6/2010Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
6/2010Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
1/2009Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joseph P Costantino Research Topics

Disease

78Breast Neoplasms (Breast Cancer)
07/2023 - 06/2002
34Neoplasms (Cancer)
07/2023 - 01/2003
11Noninfiltrating Intraductal Carcinoma (DCIS)
02/2016 - 01/2003
3Margins of Excision
12/2019 - 02/2016
3Neutropenia
09/2015 - 01/2012
3Uterine Neoplasms (Uterine Cancer)
12/2011 - 06/2006
3Endometrial Neoplasms (Endometrial Cancer)
06/2011 - 11/2005
3Cataract (Cataracts)
06/2011 - 11/2005
3Amenorrhea
03/2011 - 01/2009
3Hyperplasia
06/2010 - 02/2003
3Venous Thrombosis (Deep-Vein Thrombosis)
07/2006 - 01/2003
2Neoplasm Metastasis (Metastasis)
12/2019 - 07/2012
2Fatigue
02/2016 - 09/2015
2Hand-Foot Syndrome
09/2015 - 01/2012
2Hypertension (High Blood Pressure)
09/2015 - 01/2012
2Breast Carcinoma In Situ
05/2014 - 01/2003
2Obesity
06/2012 - 09/2011
2Endometrial Hyperplasia
12/2011 - 04/2005
2Polyps
12/2011 - 04/2005
2Leiomyoma (Uterine Fibroids)
12/2011 - 04/2005
2Ovarian Cysts (Ovarian Cyst)
12/2011 - 04/2005
2Hypersensitivity (Allergy)
10/2010 - 10/2007
2Colonic Neoplasms (Colon Cancer)
04/2010 - 06/2007
2Prostatic Neoplasms (Prostate Cancer)
04/2009 - 03/2009
2Osteoporosis
06/2006 - 06/2002
1Embolism (Embolus)
02/2016
1Musculoskeletal Pain
02/2016
1Thrombosis (Thrombus)
02/2016
1Endocarditis
09/2015
1Sudden Death
09/2015
1Triple Negative Breast Neoplasms
07/2014
1Heart Failure
11/2013
1Osteonecrosis (Kienbock's Disease)
07/2012
1Liver Diseases (Liver Disease)
07/2012
1Inflammation (Inflammations)
06/2012
1Insulin Resistance
06/2012
1Body Weight (Weight, Body)
01/2012
1Left Ventricular Dysfunction
01/2012
1Mucositis
01/2012
1Vaginal Discharge
12/2011

Drug/Important Bio-Agent (IBA)

51TamoxifenFDA LinkGeneric
07/2023 - 06/2002
18Estrogen ReceptorsIBA
07/2023 - 11/2005
17Raloxifene Hydrochloride (Evista)FDA Link
01/2014 - 06/2002
11Trastuzumab (Herceptin)FDA Link
10/2020 - 06/2008
9Cyclophosphamide (Cytoxan)FDA LinkGeneric
03/2017 - 01/2009
9Doxorubicin (Adriamycin)FDA LinkGeneric
03/2017 - 01/2009
6Paclitaxel (Taxol)FDA LinkGeneric
02/2018 - 06/2010
6Docetaxel (Taxotere)FDA Link
07/2017 - 01/2009
6Hormones (Hormone)IBA
02/2016 - 04/2008
5human ERBB2 proteinIBA
01/2021 - 06/2010
5B 31IBA
01/2019 - 12/2013
4Progesterone Receptors (Progesterone Receptor)IBA
02/2018 - 04/2006
4Bevacizumab (Avastin)FDA Link
01/2018 - 01/2012
4P-2 (P 2)IBA
07/2013 - 06/2006
4Selective Estrogen Receptor Modulators (SERM)IBA
07/2013 - 06/2010
4desintegron BIBA
11/2011 - 08/2006
3Dihydrotachysterol (AT 10)IBA
07/2023 - 08/2006
3AnthracyclinesIBA
07/2017 - 06/2010
3Anastrozole (Arimidex)FDA LinkGeneric
02/2016 - 11/2011
3GemcitabineFDA Link
09/2015 - 01/2012
2Biomarkers (Surrogate Marker)IBA
01/2019 - 04/2015
2Capecitabine (Xeloda)FDA Link
09/2015 - 01/2012
2Estrogens (Estrogen)FDA Link
04/2012 - 04/2005
2Taxoids (Taxanes)IBA
01/2012 - 06/2010
2Coloring Agents (Dyes)IBA
10/2010 - 10/2007
2Leucovorin (Folinic Acid)FDA Link
04/2010 - 06/2007
2Fluorouracil (Carac)FDA LinkGeneric
04/2010 - 06/2007
2Prostate-Specific Antigen (Semenogelase)IBA
04/2009 - 03/2009
2Monoclonal AntibodiesIBA
10/2008 - 10/2008
2Gonadal Steroid Hormones (Sex Hormones)IBA
05/2006 - 01/2006
1olaparibIBA
01/2021
1Poly Adenosine Diphosphate RiboseIBA
01/2021
1Octreotide (Sandostatin)FDA LinkGeneric
09/2015
1ErbB Receptors (EGF Receptor)IBA
08/2015
1SmokeIBA
05/2014
1B 43IBA
11/2013
1Lapatinib (GW572016)FDA Link
11/2013
1taxaneIBA
09/2013
1DNA (Deoxyribonucleic Acid)IBA
07/2013
1antineoplaston A10 (A 10)IBA
05/2013
1Clodronic Acid (Clodronate)IBA
07/2012
1Diphosphonates (Bisphosphonates)IBA
07/2012
1Insulin (Novolin)FDA Link
06/2012
1AdipokinesIBA
06/2012
1Vitamin DFDA LinkGeneric
06/2012
1LeptinIBA
06/2012
1C-Reactive ProteinIBA
06/2012
1AntimetabolitesIBA
01/2012

Therapy/Procedure

34Therapeutics
01/2021 - 01/2003
14Drug Therapy (Chemotherapy)
07/2023 - 08/2006
11Segmental Mastectomy (Lumpectomy)
12/2019 - 01/2003
10Chemoprevention
04/2012 - 01/2006
9Adjuvant Chemotherapy
01/2021 - 06/2007
6Neoadjuvant Therapy
01/2018 - 01/2012
6Radiotherapy
02/2016 - 01/2003
3Mastectomy (Mammectomy)
12/2019 - 08/2006
3Hysterectomy
06/2011 - 01/2003
3Lymph Node Excision (Lymph Node Dissection)
10/2010 - 08/2007
1Combination Drug Therapy (Combination Chemotherapy)
09/2013
1Transcutaneous Electric Nerve Stimulation (TENS)
09/2012